Sustained-release dosage forms enable prolonged action of a drug in the body. Much research has focused on overcoming the
short residence times and unpredictable gastric emptying times of drugs in sustained-release oral drug-delivery systems (1).
A floating drug-delivery system floats in the gastric juice without affecting the gastric emptying rate. It forms a cohesive
gel barrier that serves as a reservoir and releases the drug over the desired period of time. This technique helps increase
a drug's gastric residence time and reduces the variability in bioavailability (2, 3).
Metronidazole is used as an antibiotic, amebicide, and antiprotozoal, and as a gel preparation for dermatological conditions
(4–8). The drug has a wide therapeutic index for sustained-release administration (5). For example, a sustained-release oral
dosage form of metronidazole is an effective antibiotic because it is locally active in the gastric mucosa (9). The prolonged
effect of locally active metronidazole increases its clinical efficacy at eradicating Helicobacter pylori (10). Oral, sustained-release metronidazole has several advantages for treating H. pylori locally through systemic absorption (11).
Metronidazole was chosen as a model drug to develop a sustained-release floating matrix tablet because it has a half life
of 6–8 h. Methocel K15M CR (hydroxypropyl methylcellulose, Dow Chemical) is beneficial in controlling drug release in a floating
formulation, but Carbomer 934P (carboxy polymethylene–prop-2-enoic acid, ChemIndustry) enables more floating time than Methocel
K15M CR and hydroxypropyl cellulose (HPC) (12).
Metronidazole BP was obtained from Aarti Drugs. Methocel K15M CR with a molecular weight of 10–1,500 kDa, HPC, and Carbomer
934P were obtained from Eskayef Pharmaceuticals. ChemIndustry provided 1-ethenylpyrrolidin-2-one (povidone). Sodium bicarbonate,
citric acid, lactose, and magnesium stearate were provided by Wiechers and Helm.
Preparation of standard curve.
A standard curve of metronidazole hydrochloride was constructed by serially diluting an aqueous solution of the drug to obtain
the concentration in the range of 1–20 µg/mL using simulated gastric fluid without enzymes and phosphate buffer as the diluents.
The spectrophotometric analysis was performed using a Shimadzu spectrophotometer at the absorbance of 278 nm against a blank
for each solution. The measured absorbance, plotted against the respective concentration of the standard solutions, appeared
as a straight line.
Preparation of tablets.
Metronidazole tablets were prepared using rate-controlling polymers and other gas-generating excipients. Each formulation
contained 400 mg of metronidazole, 100 mg of sodium bicarbonate as a gas-generating agent, 30 mg of citric acid, 70 mg of
povidone, and 160 mg of lactose.
Polymers and excipients with various concentrations (see Table I) were mixed together by pestle carefully for 20 min. Next,
1.5% (w/w) of magnesium stearate was rubbed with the punch and die as lubricant. Each tablet was 50% (w/w) metronidazole powder.
Tablets were prepared by direct compression using a 13-mm die and flat-faced punch (KBR Press). Sufficient compression load
was applied to produce tablets with a hardness of 6–17 kg.
Table I: Properties of tablets containing Methocel K15M CR, hydroxypropyl cellulose (HPC), and Carbomer 934P in a metronidazole-based
A 32 randomized full-factorial design was used to design the formulations. Three factors were evaluated in this study at three
levels and tested in nine possible formulations. The amounts of polymers were determined as independent variables, and percentage
release as a dependent variable.